Intralesional versus intracoronary administration of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention in patients with acute coronary syndromes: A meta-analysis of randomized controlled trials

BACKGROUND: Glycoprotein IIb/IIIa inhibitors (GPIs) have been regarded as an adjuvant regimen to deal with no-reflow. However, whether intralesional (IL) administration of GPIs improves myocardial reperfusion without increasing bleeding in patients with acute coronary syndrome (ACS) compared with in...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Binjie, Liu, Zhen, Yin, Hongshan, Wang, Tao, Chen, Tao, Yang, Sen, Jiang, Zhian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
3400
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5738012/
https://www.ncbi.nlm.nih.gov/pubmed/28984776
http://dx.doi.org/10.1097/MD.0000000000008223

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5738012/
https://www.ncbi.nlm.nih.gov/pubmed/28984776
http://dx.doi.org/10.1097/MD.0000000000008223

Ejemplares similares